Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta‐analysis with focus on an Asian subpopulation

Ähnliche Einträge

• Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP ‐4 inhibitors: A multicentre, phase 4 randomized controlled trial
  von: Yun Kyung Cho, et al.
  Veröffentlicht: (2025)
• Association Between SGLT2 Inhibitors and DPP ‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses
  von: Ye‐Jee Kim, et al.
  Veröffentlicht: (2026)
• Cardiorenal outcomes and mortality with GLP ‐1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta‐analysis
  von: João Sérgio Neves, et al.
  Veröffentlicht: (2025)
• Triple oral therapy with metformin, DPP ‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)
  von: Miao Yu, et al.
  Veröffentlicht: (2025)
• A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
  von: Soo Lim, et al.
  Veröffentlicht: (2024)